The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 7
- 7 new
- Median first-year cost
- $460,500
- $3,365,039 in all
- Institutions
- 7
- 7 contact PIs
- Patents
- 1
- from 1 funded project
Awards by fiscal year
Fiscal years 2014 to 2026.
Most frequent institutions
- BOSTON CHILDREN'S HOSPITAL1
- CHILDREN'S HOSP OF PHILADELPHIA1
- JOHNS HOPKINS UNIVERSITY1
- UNIVERSITY OF ILLINOIS AT CHICAGO1
- UNIVERSITY OF ROCHESTER1
and 2 other institutions
Most frequent study sections
- Special Emphasis Panel (ZHL1 CSR-B (S1))7
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2015 | Megakaryocyte Transcription Factor Activation to Enhance In Vitro Platelet Production from Human IPSCs1R01HL130793-01 | Cantor, Alan B. | BOSTON CHILDREN'S HOSPITAL, MA | First-year cost $565,075 | Study section ZHL1 |
| FY2015 | Genetically enhanced human erythrocytes generated from expandable stem cells1R01HL130676-01 | Cheng, Linzhao | JOHNS HOPKINS UNIVERSITY, MD | First-year cost $508,325 | Study section ZHL1 |
| FY2015 | Optimization of Ex Vivo- and In Vivo- Generated Platelets1R01HL130698-01 | French, Deborah LynnGadue, Paul JPoncz, Mortimer | CHILDREN'S HOSP OF PHILADELPHIA, PA | First-year cost $506,000 | Study section ZHL1 |
| FY2015 | Erythroid precursor self-renewal1R01HL130670-01 | Palis, James | UNIVERSITY OF ROCHESTER, NY | First-year cost $460,500 | Study section ZHL1 |
| FY2015 | Controlling an Ontogenic Masterswitch to Maximize Thrombopoiesis1R01HL130550-01 | Goldfarb, Adam N. | UNIVERSITY OF VIRGINIA, VA | First-year cost $460,426 | Study section ZHL1 |
| FY2015 | Generating Human Cord-Blood-Derived Functional Megakaryocytes and platelets.1R01HL130760-01 | Mahmud, NadimMiller, William M | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | First-year cost $452,300 | Study section ZHL1 |
| FY2015 | Universal Donor Megakaryocytes1R01HL130770-01 | Russell, David W | UNIVERSITY OF WASHINGTON, WA | First-year cost $412,413 | Study section ZHL1 |
Patents from its funded projects
1 patent names 1 of the 7 funded projects.
- US 10,260,043 (opens the patent at USPTO, a PDF, in a new tab)Human Extensively Self-Renewing Erythroblasts (ESRE)Granted April 16, 2019 to University of RochesterR01HL130670 · UNIVERSITY OF ROCHESTER, NY
Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.
Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-17-0.3.6. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.